Hepatic irradiation decreases the proportion of DX5^–TRAIL⁺ lrNK cells for up to two months. by Ryosuke Nakano (4557097)

“…NK cells were divided into DX5^–TRAIL⁺ lrNK cells and DX5⁺TRAIL⁻ cNK cells. …”

Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation. by Shandiz Tehrani (3365900)

Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis-2 by Mrigank Srivastava (94935)

“…(A), data are given as fold change in cathepsin K mRNA of bleomycin-challenged cath K tg mice compared to wild-type mice. …”

Sign-tracking (ST)–Goal-tracking (GT) score for day 5. by Silvia Fuentes (4759686)

Metformin decreases CRC-like organoids viability to the same extent as current chemotherapy without significant effects on WT organoids. by Silvia Cruz-Gil (7037249)

Decreased ratio of GSH/GSSG in <i>Slc1a1-</i>HET mice. by Parisa Afshari (4423141)

Raw data used to generate the graphs shown in Figs 1B, 1E, 2B, 3B, 4B and 5A–5C of representative experiments from three independent biological repeats. by Timilehin Faboro (20175963)

Subjects:

<i>S</i>. Typhimurium coordinates protein synthesis with protein folding capacity. by Carissa Chan (18310140)

Fold change of TIL subsets in paired TNBCs (N = 12 pts including 10 prim-met, and 2 met-met specimens) using log2 ratio of metastatic versus primary TNBC (n = 10, ●) or second recu... by Ting-Fang He (5210948)

Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection. by Young-Tae Lee (467116)

ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: